Bone markers in the management of metastatic bone disease
- 30 June 2001
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 27 (3), 181-185
- https://doi.org/10.1053/ctrv.2000.0212
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretionBritish Journal of Cancer, 1999
- Markers of bone resorption in patients treated with pamidronateEuropean Journal Of Cancer, 1998
- Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinomaCancer, 1997
- Urinary Pyridinoline and Deoxypyridinoline as Potential Markers of Bone Metastasis in Patients with Prostate CancerJournal of Urology, 1996
- Metabolic effects of pamidronate in patients with metastatic bone diseaseBritish Journal of Cancer, 1996
- Pyridinium cross‐links as urinary markers of bone metastases in patients with prostate cancerBritish Journal of Urology, 1996
- The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone diseaseJournal of Clinical Endocrinology & Metabolism, 1995
- Metastases in carcinoma.Analysis of 1000 autopsied casesCancer, 1950